Axsome Therapeutics is trading 4.24% lower at $149.46 on October 23, 2026, amid biotech and broader market weakness; no clear company-specific catalyst has surfaced. - XBI is down 2.08%, while major indices are also lower. - Cautious sentiment amid geopolitical and oil-price concerns may be part of the backdrop, but available reporting does not directly confirm the cause of the stock’s decline.